recent publications

• academic article

  • Bhatt, D. L., Pare, G., Eikelboom, J. W., Simonsen, K. L., Emison, E. S., Fox, K. A. A., Steg, P. G., Montalescot, G., Bhakta, N., Hacke, W., Flather, M. D., Mak, K. H., et al. The relationship between cyp2c19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: The charisma genetics study European Heart Journal  2012 33:2143-2150  DOI:10.1093/eurheartj/ehs059  PMID:22450429
  • Bhatt, D. L., Flather, M. D., Hacke, W., Berger, P. B., Black, H. R., Boden, W. E., Cacoub, P., Cohen, E. A., Creager, M. A., Easton, J. D., Hamm, C. W., Hankey, G. J., et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the charisma trial Journal of the American College of Cardiology  2007 49:1982-1988  DOI:10.1016/j.jacc.2007.03.025  PMID:17498584
  • Bhatt, D. L., Fox, K. A. A., Hacke, W., Berger, P. B., Black, H. R., Boden, W. E., Cacoub, P., Cohen, E. A., Creager, M. A., Easton, J. D., Flather, M. D., Haffner, S. M., et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events New England Journal of Medicine  2006 354:1706-1717  DOI:10.1056/NEJMoa060989  PMID:16531616
  • Bhatt, D. L., Fox, K. A., Hacke, W., Berger, P. B., Black, H. R., Boden, W. E., Cacoub, P., Cohen, E. A., Creager, M. A., Easton, J. D., Flather, M. D., Haffner, S. M., et al. A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial American Heart Journal  2005 150:401.e1-401.e7  DOI:10.1016/j.ahj.2005.03.017  PMID:16169314